CEBPA and ovarian cancer: The possible reason for our analysis is that CEBPA has an extensive mutation in human tumors, and the mutation rate of CEBPA in ovarian cancer may have a higher mutation rate, thus inhibiting the anti-proliferative effect of CEBPA.